AnnJi Pharmaceutical Co., Ltd.

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. Its pipeline includes AJ201 for spinal and bulbar muscular atrophy, AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy, and AJ303, an anti-fibrotic and anti-inflammatory compound for idiopathic pulmonary fibrosis. The company was founded in 2014 and is based in Taipei, Taiwan.